Junctional adhesion molecule-A is co-expressed with HER2 in breas.pdf (522.82 kB)
0/0

Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.

Download (522.82 kB)
journal contribution
posted on 22.11.2019 by Kieran Brennan, Elaine A. McSherry, Lance Hudson, Elaine W. Kay, Arnold DK Hill, Leonie S. Young, Ann M. Hopkins

Junctional adhesion molecule-A (JAM-A) is a membranous cell-cell adhesion protein involved in tight-junction formation in epithelial and endothelial cells. Its overexpression in breast tumors has recently been linked with increased risk of metastasis. We sought to identify if JAM-A overexpression was associated with specific subtypes of breast cancer as defined by the expression of human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor. To this end, JAM-A immunohistochemistry was performed in two breast cancer tissue microarrays. In parallel, cross-talk between JAM-A, HER2 and ER was examined in several breast cell lines, using complementary genetic and pharmacological approaches. High JAM-A expression correlated significantly with HER2 protein expression, ER negativity, lower patient age, high-grade breast cancers, and aggressive luminal B, HER2 and basal subtypes of breast cancer. JAM-A and HER2 were co-expressed at high levels in vitro in SKBR3, UACC-812, UACC-893 and MCF7-HER2 cells. Knockdown or functional antagonism of HER2 did not alter JAM-A expression in any cell line tested. Interestingly, however, JAM-A knockdown decreased HER2 and ER-α expression, resulting in reduced levels of phospho-(active) AKT without an effect on the extracellular signal-related kinase phosphorylation. The downstream effects of JAM-A knockdown on HER2 and phospho-AKT were partially reversed upon treatment with the proteasomal inhibitor MG132. We conclude that JAM-A is co-expressed with HER2 and associates with aggressive breast cancer phenotypes. Furthermore, we speculate that JAM-A may regulate HER2 proteasomal degradation and activity, potentially offering a promise as a therapeutic target in HER2-positive breast cancers.

History

Comments

This article is also available at http://www.ncbi.nlm.nih.gov/pubmed/22751120 or http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2012276a.html

Published Citation

Brennan K, McSherry EA, Hudson L. Kay EW, Hill AD, Young LS, Hopkins AM. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling. Oncogene. July, 2012 [Epub ahead of print]

Publication Date

01/07/2012

Publisher

Nature Publishing Group

PubMed ID

22751120

Exports

Logo branding

Categories

Exports